#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alport's syndrome Leiomyosarcoma Rheumatoid arthritis Mantle cell lymphoma stage IV Macular telangiectasia Indolent systemic mastocytosis Neurodermatitis Hypoxic-ischaemic encephalopathy Conjunctivitis allergic Choroid melanoma Andersen-Tawil syndrome Autoimmune myositis Barth syndrome Non-Hodgkin's lymphoma unspecified histology indolent Meningococcal immunisation More trials…

    Learn about Rare Diseases

    Haemophilia A without inhibitors – Basic Information Cytokine release syndrome – Basic Information Ewing’s sarcoma recurrent – Trials in Disease Hereditary neuropathic amyloidosis – Treatment Adrenocortical carcinoma – Diagnostics Indolent systemic mastocytosis – Life with Disease Retinitis pigmentosa – Life with Disease Progressive supranuclear palsy – Treatment Piriformis syndrome – Trials in Disease Pulmonary fibrosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    SAR444336 Chloroprocaine Hydrochloride Amantadine Hydrochloride Cefepime Munc-Cd34 Ribonucleic Acid K10 Beclometasone Dipropionate Somapacitan Emtricitabine Clebopride Hydrogen Maleate Efavirenz Ethinylestradiol Taminadenant S095035 Axicabtagene Ciloleucel Iph6501 Alxn2220 CICLOPIROX Blood And Related Products Human Normal Immunoglobulin More therapies…

    Learn about Your Condition

    Benign neoplasm of ureter Chronic lymphocytic leukaemia Renal cell carcinoma Barrett's oesophagus Chondrocalcinosis Neuroblastoma Rhabdomyosarcoma recurrent Radius fracture Short-bowel syndrome Normal pressure hydrocephalus Food allergy Advanced systemic mastocytosis Endometrial cancer stage IV Myxoid liposarcoma Pterygium More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o….

Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.

Ul. Jana Pawla II 35, Tomaszow Mazowiecki, 97-200, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Safety and Tolerability of Alisertib Sodium and Paclitaxel in Patients with Small Cell Lung Cancer (Phase 2 Study)

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Alisertib Sodium
    • Paclitaxel
    France Poland Spain

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    • Tucatinib
    • Trastuzumab
    Austria Belgium Czechia France Germany Hungary +5

  • Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive gastric cancer
    Investigated Drugs:
    • Trastuzumab
    • Capecitabine
    • Cisplatin
    Austria Belgium France Germany Hungary Italy +3

  • Study on the Effectiveness and Safety of Belinostat and Pralatrexate with Drug Combination for Newly Diagnosed Peripheral T-Cell Lymphoma Patients

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Peripheral T-cell lymphoma unspecified
    Investigated Drugs:
    • Belinostat
    • Pralatrexate
    • Prednisone
    France Germany Hungary Italy Poland Spain

  • A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Cachexia
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • Ponsegromab
    Belgium Bulgaria France Germany Italy Poland +2

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Goserelin
    • Tamoxifen Citrate
    • Triptorelin
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma stage III
    Investigated Drugs:
    • Enomimeran
    • Gindameran
    • Ontasameran
    Germany Italy Poland Spain

  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan and Drug Combination for Patients with HER2-Positive Gastric, GEJ, and Esophageal Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Trastuzumab
    • Capecitabine
    • Cisplatin
    Germany Italy The Netherlands Poland Spain

  • Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Atezolizumab
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Regorafenib
    Belgium France Germany Hungary Poland Portugal +1

  • Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Goserelin Acetate
    • Leuprorelin Acetate
    • Abemaciclib
    Austria Belgium Bulgaria France Germany Hungary +6
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!